Emergent BioSolutions Inc. EBS 深 沪
等待开盘 03-31 09:30:00 美东时间
8.05
+0.120
+1.51%
华盛通- 最 高8.1399
- 今 开8.10
- 成交量 83.37万股
- 最 低 7.94
- 昨 收 7.93
- 总市值 4.17亿
- 52周最高 14.06
- 市盈率 静 8.68
- 换手率 1.61%
- 52周最低 4.02
- 委 比 33.70%
- 总股本 5177.09万
- 历史最高 137.61
- 量 比 1.02
- 振 幅 2.52%
- 历史最低 1.42
- 每 手 1
- 风险率 2.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Emergent BioSolutions Secures ~$54M Contract To Provide CNJ-016 Vaccinia Immune Globulin Intravenous To U. S. Department of Health And Human Services' Administration For Strategic Preparedness And Response For Smallpox Preparedness; Gets New $6.6M Incremental Orders With Undisclosed Global Federal Partner For ACAM2000
Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the
03-26 04:22
Emergent BioSolutions secures $60M contracts
Emergent BioSolutions (EBS) announced on Wednesday it has secured a contract award valued at approximately $54M to deliver CNJ-016® to the Administration for Strategic Preparedness and Response (ASPR...
03-26 04:21
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
Emergent BioSolutions has secured a $54 million USD contract to provide VIGIV for smallpox preparedness with the U.S. government and a $6.6 million USD order for ACAM2000 with an international partner. The company also recently executed a $140 million CAD agreement with Canada for生物威胁 preparedness. Both products are critical for global health security. VIGIV treats vaccinia vaccination complications, while ACAM2000 prevents smallpox and mpox. The...
03-25 20:15
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Emergent BioSolutions Inc. Files Initial Beneficial Ownership Statement for Director John D. Fowler Jr
Emergent BioSolutions Inc. Files Initial Beneficial Ownership Statement for Director John D. Fowler Jr Emergent BioSolutions Inc. filed an initial statement of beneficial ownership (Form 3) reporting John D. Fowler Jr as a Director. The full filing can be accessed through the link below. Disclaimer:
03-06 10:38
Emergent BioSolutions shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY26 sales guidance below estimates.
Emergent BioSolutions shares are trading lower after the company reported worse...
02-27 05:57
Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
Emergent Biosolutions ( ($EBS) ) has provided an update. On February 26, 2026, ...
02-27 05:33
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Emergent BioSolutions Obtains FDA Approval For Its Supplemental New Drug Application For New Multipack Configurations Of OTC NARCAN Nasal Spray
Today, Emergent BioSolutions (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC)
02-13 07:02
FDA Approves Multipack Options for Emergent BioSolutions’ NARCAN Nasal Spray
FDA Approves Multipack Options for Emergent BioSolutions’ NARCAN Nasal Spray Emergent BioSolutions Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) regarding new multipack configurations of over-the-counter (OTC) NARCAN® Nas
02-13 07:00
